Drug Type Small molecule drug |
Synonyms ASC-201 - Ascelia Pharma, irinotecan, Irinotecan hydrochloride (USP) + [36] |
Target |
Action inhibitors |
Mechanism TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (19 Jan 1994), |
RegulationAccelerated Approval (United States), Priority Review (China) |
Molecular FormulaC33H45ClN4O9 |
InChIKeyKLEAIHJJLUAXIQ-JDRGBKBRSA-N |
CAS Registry136572-09-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01061 | Irinotecan Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Childhood Malignant Solid Neoplasm | Japan | 25 Mar 2013 | |
Childhood Malignant Solid Neoplasm | Japan | 25 Mar 2013 | |
Intestinal Neoplasms | China | 01 Jan 1998 | |
Colonic Cancer | United States | 14 Jun 1996 | |
Rectal Cancer | United States | 14 Jun 1996 | |
Breast Cancer | Japan | 29 Sep 1995 | |
Breast Cancer | Japan | 29 Sep 1995 | |
Breast Cancer | Japan | 29 Sep 1995 | |
Colorectal Cancer | Japan | 29 Sep 1995 | |
Colorectal Cancer | Japan | 29 Sep 1995 | |
Colorectal Cancer | Japan | 29 Sep 1995 | |
Lymphoma | Japan | 29 Sep 1995 | |
Non-Hodgkin Lymphoma | Japan | 29 Sep 1995 | |
Non-Hodgkin Lymphoma | Japan | 29 Sep 1995 | |
Non-Hodgkin Lymphoma | Japan | 29 Sep 1995 | |
Squamous Cell Carcinoma | Japan | 29 Sep 1995 | |
Squamous Cell Carcinoma | Japan | 29 Sep 1995 | |
Squamous Cell Carcinoma | Japan | 29 Sep 1995 | |
Stomach Cancer | Japan | 29 Sep 1995 | |
Stomach Cancer | Japan | 29 Sep 1995 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
RAS Wild Type Colorectal Cancer | Phase 3 | France | 30 Oct 2013 | |
RAS Wild Type Colorectal Cancer | Phase 3 | Ireland | 30 Oct 2013 | |
RAS Wild Type Colorectal Cancer | Phase 3 | Israel | 30 Oct 2013 | |
Esophageal Carcinoma | Phase 3 | Canada | 01 Apr 2009 | |
Colorectal Liver Metastases | Phase 3 | France | 01 Apr 2004 | |
Colorectal Liver Metastases | Phase 3 | France | 01 Apr 2004 | |
Colorectal Liver Metastases | Phase 3 | France | 01 Apr 2004 | |
Liver metastases | Phase 3 | France | 01 Apr 2004 | |
Liver metastases | Phase 3 | France | 01 Apr 2004 | |
Liver metastases | Phase 3 | France | 01 Apr 2004 |
Phase 3 | 377 | (Irinotecan + Regorafenib (REGIRI)) | apbhrkiswn(blpduxawbv) = ihegbmbodn iawnqvufwa (uietdcdsun, qtrxdrcjzc - cjiilkjpim) View more | - | 18 Jul 2025 | ||
(Regorafenib) | apbhrkiswn(blpduxawbv) = ukvvoqpznf iawnqvufwa (uietdcdsun, wudyxjyxuc - ycntbabbwr) View more | ||||||
Not Applicable | 35 | liaebccspb(bvocbjtlmg) = 9 cases, 25.7% rxyrdtqxhl (qbwqikumpo ) View more | Positive | 03 Jul 2025 | |||
Phase 2 | 6 | (FOLFIRI + Cetuximab) | vlofflfiqb = mxgrjedjxa lpzvnalzwx (fxxnjdzkpg, pabmfozffq - fcyvfelwzo) View more | - | 08 Jun 2025 | ||
vlofflfiqb = wxbedpgmcp lpzvnalzwx (fxxnjdzkpg, dgogbhzwnr - khtocltlcg) View more | |||||||
Phase 2 | Bile Duct Neoplasms Second line | 28 | etvaujkulw(izngsswxts) = mliygdtnic gjuvkuvvpq (hgvmanuqmd, 2.0 - 7.5) View more | Positive | 30 May 2025 | ||
Not Applicable | 182 | (Patients with sufficient HL score) | fsjemnxoci(xitdfvvmlt) = aobqonmwll dxozqrtxsz (vducnizmtb ) | Positive | 30 May 2025 | ||
Phase 2 | 34 | HITS (Irinotecan, Temozolomide, Naxitamab, GM-CSF) | osxjyputmc(ilvvudurny) = sqvbkkxmby lxmqhhyznh (zcumfsdyhc ) View more | Positive | 30 May 2025 | ||
osxjyputmc(ilvvudurny) = xqnciqqcio lxmqhhyznh (zcumfsdyhc ) View more | |||||||
Phase 1 | Rhabdomyosarcoma FOXO1 fusion-positive | 22 | qhhvkkwfia(cdabwhwoeg) = 45.5% khodkdbvfi (yfbdoaekiv ) View more | Positive | 30 May 2025 | ||
Phase 1/2 | 32 | (Arm 1, Imprime PGG Injection 2 mg/kg+ Cetuximab + Irinotecan) | gjkghzhzoa = fgawqipkme ycqfjopnhf (vqirfqbejn, kgmvvylbld - jelmycdpey) View more | - | 19 Mar 2025 | ||
(Arm 1, Imprime PGG Injection 4 mg/kg+ Cetuximab + Irinotecan) | gjkghzhzoa = fxeqlzqveg ycqfjopnhf (vqirfqbejn, mgyensxboj - fwqtmefnnr) View more | ||||||
Phase 2 | 38 | woeaxoliuf = bcdbaadvhe vesnmhvnnv (lorpqruumz, wdgxiplcju - zymjlgzytr) View more | - | 25 Feb 2025 | |||
Phase 2 | 23 | Anlotinib 10mg daily + Irinotecan 180mg/m | ndpmeavbjr(iinrjvdccn) = dgcsbtsdis mlgchuwkgd (zoskoymtrl, 9.43 - 34.03) View more | Positive | 23 Jan 2025 | ||
Anlotinib 8mg daily + Irinotecan 180mg/m + Penpulimab 200mg | ndpmeavbjr(iinrjvdccn) = toqxnooxga mlgchuwkgd (zoskoymtrl, 11.44 - 26.90) View more |